Incidence of myeloproliferative markers and hereditary thrombocythemia markers in 32 children with ET
| Marker . | Sporadic thrombocythemia . | Familial thrombocythemia . |
|---|---|---|
| No. | 20 | 12 |
| JAK2V617F mutation, no. patients (%) | 8 (40) | 0 |
| Exon 12 JAK2 mutations, no. patients (%) | 0 | 0 |
| TPO mutations, no. patients (%) | 0 | 0 |
| MPL mutations, no. patients (%) | 0 | 10 (83) |
| EEC growth, no. patients (%) | 10 (50) | 3 (25) |
| Clonal hematopoiesis, no. patients* | 8/13 | 0/5 |
| ET diagnosis, no. patients (%) | 20 (100) | 12 (100) |
| Marker . | Sporadic thrombocythemia . | Familial thrombocythemia . |
|---|---|---|
| No. | 20 | 12 |
| JAK2V617F mutation, no. patients (%) | 8 (40) | 0 |
| Exon 12 JAK2 mutations, no. patients (%) | 0 | 0 |
| TPO mutations, no. patients (%) | 0 | 0 |
| MPL mutations, no. patients (%) | 0 | 10 (83) |
| EEC growth, no. patients (%) | 10 (50) | 3 (25) |
| Clonal hematopoiesis, no. patients* | 8/13 | 0/5 |
| ET diagnosis, no. patients (%) | 20 (100) | 12 (100) |
The number of patients fulfilling the proposed revised WHO diagnostic criteria for ET is shown in the lower part of the table.
Number of patients with clonal hematopoiesis among all female patients.